• Phase 2 study THR-149 in Diabetic Macular Edema (DME): start of study delayed until COVID-19 related safety considerations allow. Preparation work to continue as planned.
  • Phase 2 study THR-687 in Diabetic Macular Edema (DME): preparations to start study in Q1 2021. Currently no change.
  • Phase 1/2a study TB-403 in medulloblastoma (Oncurious): study recruiting.

Company does not expect COVID-19 to impact current cash management guidance as communicated in its FY19 Business Update (March 12, 2019)

Attachments

  • Original document
  • Permalink

Disclaimer

Oxurion NV published this content on 28 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 March 2020 14:32:05 UTC